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Summary
 
Although it has been demonstrated that certain cytokines, particularly proinflammatory cyto-
kines, can enhance ongoing viral replication in peripheral blood mononuclear cells (PBMCs) of
HIV-1–infected individuals, it is unclear what role these cytokines play in the induction of
HIV-1 replication in latently infected, resting CD4
 
1
 
 T cells. This study demonstrates that the
in vitro
 
 
 
combination of the proinflammatory cytokines interleukin (IL)-6 and tumor necrosis
factor (TNF)-
 
a
 
 together with the immunoregulatory cytokine IL-2 are potent inducers of viral
replication in highly purified, latently infected, resting CD4
 
1
 
 T cells derived from HIV-infected
individuals who are antiretroviral therapy–naive as well as those who are receiving highly ac-
tive antiretroviral therapy (HAART). Viral replication induced by this combination of cyto-
kines was completely suppressed in the presence of HAART in vitro
 
. 
 
Given that an array of
cytokines, including IL-6, TNF-
 
a
 
, and IL-2, are copiously expressed in the microenvironment
of the lymphoid tissues, which harbor the latent viral reservoirs, induction of HIV by this com-
bination of cytokines may in part explain the commonly observed reappearance of detectable
plasma viremia in HIV-infected individuals in whom HAART was discontinued. Moreover,
since it is likely that these infected cells die upon activation of virus and that HAART prevents
spread of virus to adjacent cells, the observation that this combination of cytokines can mark-
edly induce viral replication in this reservoir may have important implications for the activa-
tion-mediated diminution of the latent reservoir of HIV in patients receiving HAART.
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C
 
ytokines are important effector molecules in the initi-
ation and propagation of inflammatory and immune
responses; in addition, certain cytokines mediate a number
of important immunoregulatory functions (1). The role of
cytokines in the pathogenesis of HIV disease has been ex-
tensively studied (2–5). It has been demonstrated by in
vitro
 
 
 
experiments that HIV replication in PBMCs of HIV-
infected individuals is finely regulated by a variety of en-
dogenous cytokines acting in an autocrine and paracrine
manner (5, 6). Cytokine-rich supernatants derived from
cultures of PBMCs from normal individuals were first
shown to induce the expression of HIV-1 in chronically
infected cell lines (7, 8). Subsequently, a variety of individ-
ual cytokines, particularly proinflammatory cytokines, were
demonstrated to induce HIV expression either endoge-
nously or when added to acutely or chronically infected
cell cultures (3, 4, 9). Of these, IL-1, IL-6, and TNF-
 
a
 
have been implicated in the pathogenesis of HIV-1 as di-
rect modulators of virus expression (3, 10–13) and higher
levels of these cytokines have been detected in the sera of
infected individuals; furthermore, secretion of these cyto-
kines is increased in PBMCs of infected individuals (14–18).
For these reasons, selective cytokine inhibitors such as IL-1
receptor antagonist or agents that neutralize TNF-
 
a
 
 have
been suggested as potential therapeutic strategies aimed at
the control of viral replication (13, 19–23).
Recently, a small but detectable reservoir of latently
infected, resting CD4
 
1
 
 T cells has been shown to persist
in patients receiving highly active antiretroviral therapy
(HAART)
 
1
 
 and in whom plasma viremia had fallen to be-
low the level of detectability of commonly used assays (24–
26). The presence of this latent reservoir of HIV is of con-
siderable concern since these cells remain as a potential
source of reactivation of viral replication. In this regard,
these cells reside predominantly in the microenvironment
of lymphoid tissue (27), where endogenous cytokine secre-
 
1
 
Abbreviation used in this paper:
 
 HAART, highly active antiretroviral therapy.
  
84
 
Induction of HIV-1 Replication in Latently Infected CD4
 
1
 
 Cells
 
tion regularly occurs in response to normal antigenic stim-
uli (2, 28–32).
In this study, we demonstrate that the in vitro
 
 
 
combina-
tion of cytokines IL-2, IL-6, and TNF- 
 
a
 
 has a profound
effect on reactivation of HIV-1 replication in latently in-
fected, resting CD4
 
1
 
 T cells both from antiretroviral naive
patients and from patients who were receiving HAART
and in whom plasma viremia was markedly suppressed, in-
cluding some patients in whom plasma viremia was below
detectable levels. In vitro
 
 
 
HAART prevents the spread of
virus in cytokine-induced cultures. These findings may ex-
plain the reappearance of plasma viremia in patients in
whom HAART is discontinued due to drug toxicity or
lack of compliance (33). In addition, since cytokines alone
can reactivate HIV-1 replication in latently infected, resting
CD4
 
1
 
 T cells, and since these cells probably die upon reac-
tivation, it is conceivable that a strategy of administration of
cytokines together with HAART might result in a diminu-
tion of this reservoir of latently infected cells.
 
Materials and Methods
 
Patient Population.
 
Six HIV-1–seropositive patients who were
naive to antiretroviral therapy, and seven patients who were re-
ceiving HAART (Table 1) were subjected to apheresis in order
to obtain PBMCs according to protocols approved by the Na-
tional Institute of Allergy and Infectious Diseases and the Univer-
sity of Washington Institutional Review Boards.
 
Isolation of Resting CD4
 
1
 
 T Cells.
 
Resting CD4
 
1
 
 T cells were
isolated from peripheral blood of HIV-1–infected individuals us-
ing a combination of magnetic bead depletion and fluorescent ac-
tivated cell sorting techniques as described previously (27).
 
Micro Coculture Assay.
 
To determine the frequency of latently
infected, resting CD4
 
1
 
 T cells from patients carrying replication
competent HIV-1, micro coculture assays were carried out as de-
scribed previously (27).
 
Cytokines and Cell Cultures.
 
After isolation of resting CD4
 
1
 
T cells from HIV-1–infected individuals, cells (2.0–10 
 
3 
 
10
 
6
 
)
were incubated with complete medium consisting of RPMI sup-
plemented with 10% FCS, penicillin–streptomycin, and 
 
l
 
-glutamine
in a tissue culture plate with the following cytokines: IL-2 (100
U/ml; Boehringer Mannheim, Indianapolis, IN), IL-1
 
b
 
 (5 ng/ml;
R&D Systems, Minneapolis, MN), IL-4 (3 ng/ml; R&D Sys-
tems), IL-6 (5 ng/ml; R&D Systems), TNF-
 
a
 
 (2.5 ng/ml; R&D
Systems), or with the combination of IL-2, IL-6, and TNF-
 
a
 
.
Purified resting CD4
 
1
 
 T cells were also incubated with complete
medium in the absence of any cytokines as a negative control. As
a positive control, the same number of cells were incubated with
anti-CD3 antibody (OKT3) in the presence of 2 
 
3 
 
10
 
6
 
 irradiated
PBMCs from HIV-1–seronegative individuals as feeder cells. To
examine the inhibitory role of glucocorticoids in the induction of
HIV-1 replication in latently infected, resting CD4
 
1
 
 T cells by
cytokines, dexamethasone (10
 
2
 
8 
 
M; Calbiochem, La Jolla, CA)
was added to cultures containing the combination of three cyto-
kines or anti-CD3 antibody. Cultures were incubated in a 37
 
8
 
C
CO
 
2
 
 incubator for 9 d, and supernatants from each culture were
removed on days 3, 6, and 9 for determination of HIV-1 p24 by
ELISA (Coulter Corp., Miami, FL). To examine the effects of in
vitro
 
 
 
antiretroviral agents on the combination of cytokines or
anti-CD3 induced viral replication, zidovudine (AZT; 4 
 
m
 
M;
Sigma Chemical Co., St. Louis, MO), lamivudine (3TC; 5 
 
m
 
M;
gift from Dr. Raymond Schnazi, Emory University, Atlanta,
 
Table 1.
 
Profiles of HIV-1–infected Patients
 
Patient
CD4
count
Plasma
HIV RNA
 
*
 
Antiretroviral
treatment
Months receiving
HAART
 
‡
 
Infectious
viral load
 
§
 
cells/
 
m
 
l copies/ml infectious U/10
 
6
 
 cells
 
1 520 14,394 NA NA 81.7
2 540 47,704 NA NA 81.7
3 490 10,414 NA NA 8.1
4 324 29,216 NA NA 205.8
5 399 9,032 NA NA 8.1
6 602 12,157 NA NA 40.5
7 638 1,330 AZT, 3TC, Ritonavir 14.0 5.7
8 367 2,520 AZT, 3TC, Indinavir 15.0 40.1
9 1,176 1,034 AZT, 3TC, Indinavir 1.0 3.2
10 648
 
,
 
50 AZT, 3TC, Indinavir 2.5 0.5
11 790 343 AZT, 3TC, Indinavir 2.8 1.6
12 353
 
,
 
50 AZT, 3TC, Indinavir 18.0 0.5
13 689
 
,
 
50 ddI, 3TC, Indinavir 16.0 0.5
 
NA
 
, not applicable; 
 
AZT
 
, zidovudine; 
 
3TC
 
, lamivudine; 
 
ddI
 
, didanosine.
 
*
 
Plasma HIV RNA was measured using the ultrasensitive reverse transcriptase PCR assay (Roche Labs.) with a detection limit of 50 copies/ml.
 
‡
 
Indicates the number of months after the start date of protease inhibitor.
 
§
 
Determined by limiting dilution micro coculture assay by a maximum likelihood method (47). 
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GA), and the protease inhibitor indinavir (10 
 
m
 
M; Merck, Rah-
way, NJ) were added to the media.
 
Flow Cytometric Analysis and Cell Proliferation Assays.
 
To mea-
sure cytokine-induced cellular activation in latently infected, rest-
ing CD4
 
1
 
 T cells, flow cytometric analysis of the expression of
activation markers and thymidine incorporation assays were car-
ried out. Resting CD4
 
1
 
 T cells that had been incubated with var-
ious cytokines were stained with PE-conjugated anti-CD25
(Becton Dickinson, San Jose, CA) and PE-conjugated anti–HLA-
DR antibodies (Becton Dickinson) along with FITC-conjugated
anti-CD4 antibody (Becton Dickinson) 6 d after incubation. On
day 6, [
 
3
 
H]thymidine incorporation was measured in resting
CD4
 
1
 
 T cells that had been incubated with the above cytokines
or with anti-CD3 antibody.
 
Results
 
Cytokine-induced Cellular Activation in Latently Infected,
Resting CD4
 
1
 
 T Cells.
 
The replication of HIV-1 is inti-
mately associated with the state of cellular activation of sus-
ceptible cell populations (2, 28). In this regard, we first in-
vestigated the role of individual cytokines or combinations
of cytokines on the activation of highly enriched, resting
CD4
 
1
 
 T cells from HIV-1–seropositive patients by exam-
ining the expression of cell surface activation markers
CD25 and HLA-DR. As shown in Table 2, in the absence
of cytokines or any other activating stimuli, purified resting
CD4
 
1
 
 T cells from infected individuals expressed no mea-
surable CD25 or HLA-DR on their cell surfaces. After a 6-d
incubation in vitro, only IL-2 and IL-4 induced slight in-
creases in activation markers on resting CD4
 
1
 
 T cells.
However, the combination of IL-2, IL-6, and TNF-
 
a
 
showed marked increases in CD25 and HLA-DR expres-
sion. The induction of cellular activation in purified resting
CD4
 
1
 
 T cells by the combination of three cytokines was
further confirmed by the cellular incorporation of DNA
precursor thymidine (Fig. 1). With the exception of IL-2,
which induced a slight degree of cellular proliferation, no
individual cytokine resulted in active proliferation of rest-
ing CD4
 
1
 
 T cells. Cells stimulated with anti-CD3 anti-
body showed profound cellular activation as judged by
both the expression of activation markers and [
 
3
 
H]thymi-
dine incorporation, confirming that purified resting CD4
 
1
 
T cells are fully capable of undergoing cellular prolifera-
tion.
 
Induction of HIV-1 Replication by the Combination of IL-2,
IL-6, and TNF-
 
a
 
 in Latently Infected, Resting CD4
 
1
 
 T Cells
from Antiretroviral Drug–naive Patients.
 
Given the fact that
the combination of IL-2, IL-6, and TNF-
 
a
 
 potently acti-
vates resting CD4
 
1
 
 T cells as described above, we first ex-
amined the inducibility of replication-competent HIV-1 in
latently infected, resting CD4
 
1
 
 T cells from antiretroviral
 
Table 2.
 
Cytokine-mediated Cellular Activation in Latently Infected, Resting CD4
 
1
 
 T Cells
 
Cytokine added % CD4
 
1
 
/HLA-DR
 
1
 
% CD4
 
1
 
/CD25
 
1
 
Day 0 No cytokine 0.7 0.0
Day 6 No cytokine 1.0 1.2
IL-1
 
b
 
0.8 0.9
IL-2 5.7 3.3
IL-4 3.2 5.0
IL-6 1.5 1.0
TNF-
 
a
 
0.5 0.4
IL-2/IL-6/TNF-
 
a
 
23.7 8.3
anti-CD3-stimulated 50.6 92.2
Purified, resting CD4
 
1
 
 T cells from one HIV-1–seronegative and two HIV-1–infected individuals were incubated with the indicated single cyto-
kine, combination of cytokines, or with anti-CD3 antibody for 6 d and the expression of CD25 and HLA-DR was determined by FACS. Percentage
of CD4/CD25- and CD4/HLA-DR-positive cells are indicated. A representative set of results from patient no. 2 is shown.
Figure 1. Cytokine-induced cellular proliferation in latently infected,
resting CD41 T cells. Highly enriched (.99%) resting CD41 T cells
from one HIV-1–seronegative and two HIV-1–infected individuals were
incubated with the indicated individual cytokines, a combination of cy-
tokines, or anti-CD3 antibody for 6 d, and [3H]thymidine incorporation
by 104 resting CD41 T cells was measured. A representative set of results
from patient no. 2 is shown. 
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Figure 2. Induction of HIV-1 replication by the combination of IL-2, IL-6, and TNF-a in latently infected, resting CD41 T cells from antiretroviral
drug–naive patients. Resting CD41 T cells from infected patients were isolated and further incubated with no cytokine, individual cytokines as indicated,
the combination of IL-2, IL-6, and TNF-a, or anti-CD3 antibody with irradiated PBMCs from HIV-1–seronegative individuals. In addition, cells were
incubated with the combination of IL-2, IL-6, and TNF-a or anti-CD3 antibody in the presence of three drugs (AZT, 3TC, and Indinavir; see Materials
and Methods). Supernatants from each culture were removed on days 3, 6, and 9, and HIV-1 p24 was measured by ELISA.
 
Figure 3.
 
Induction of HIV-1 replication by the combination of IL-2, IL-6, and TNF- 
 
a
 
 in latently infected, resting CD4
 
1
 
 T cells from patients re-
ceiving HAART. Resting CD4
 
1
 
 T cells from infected patients were isolated and further incubated with no cytokine, individual cytokines as indicated,
the combination of IL-2, IL-6, and TNF-
 
a
 
, or anti-CD3 antibody with irradiated PBMCs from HIV-1–seronegative individuals. In addition, cells were
incubated with the combination of IL-2, IL-6, and TNF-
 
a
 
 or anti-CD3 antibody in the presence of three drugs (AZT, 3TC, and Indinavir; see Materials
and Methods). Supernatants from each culture were removed on days 3, 6, and 9, and HIV-1 p24 was measured by ELISA. 
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therapy–naive, HIV-1–seropositive individuals using indi-
vidual cytokines and combinations of cytokines in vitro.
Despite the fact that highly purified, resting CD41 T cells
from all patients carried replication-competent HIV-1 with
a frequency determined by micro coculture assay ranging
from 8.1 to 205.8 infectious units per 106 resting CD41
T cells (Table 1), measurable p24 was not detected in cul-
tures containing neither cytokines nor anti-CD3 antibody
throughout the entire incubation period (Fig. 2). Among
the individual cytokines, only IL-2 had a slight effect on the
induction of HIV-1 expression in latently infected, resting
CD41 T cells (Fig. 2). However, cultures incubated with
the combination of IL-2, IL-6, and TNF-a had a dramatic
increase in HIV-1 replication. The level of viral production
induced by this cytokine combination was equivalent to
that of cells stimulated with anti-CD3 antibody. When a
combination of three antiretroviral drugs was added to the
cultures incubated with the three cytokine combination or
with anti-CD3 antibody, viral replication was completely
suppressed as shown in Fig. 2.
Induction of HIV-1 Replication by the Combination of IL-2,
IL-6, and TNF-a in Latently Infected, Resting CD41 T cells
from Patients Receiving HAART. We and others have re-
cently reported that HIV-1–infected individuals receiving
HAART for prolonged periods of time with no detectable
plasma viremia carry a small number of latently infected,
resting CD41 T cells that produce infectious HIV-1 upon
mitogenic stimulation in vitro (24–26). In this regard, we
sought to determine whether activation of HIV-1 replica-
tion can be achieved by cytokines alone in the absence of a
potent mitogenic stimulus in latently infected, resting
CD41 T cells from patients who had been receiving
HAART for considerable periods of time and in whom
plasma viremia was markedly suppressed. The frequency of
latently infected, resting CD41 T cells carrying replication-
competent HIV-1 from these patients ranged from 0.5 to
40.1 infectious units per 106 resting CD41 T cells (Table
1). When purified resting CD41 T cells from these patients
were incubated with individual cytokines, including IL-2,
no significant HIV-1 replication was detected in the super-
natants (Fig. 3). However, the combination of IL-2, IL-6,
and TNF-a effectively induced HIV-1 replication in this
population of cells from seven out of seven patients receiving
HAART, three of whom (patient nos. 10, 12, and 13) had
no detectable plasma viremia as determined by the ultrasen-
sitive reverse transcriptase PCR assay (Roche Labs., Nutley,
NJ) with a detection limit of 50 copies of HIV-1 RNA per
milliliter of plasma. As in patients receiving no antiretrovi-
ral drugs, triple combination of antiretroviral drugs in vitro
completely abolished HIV-1 replication induced by either
the cytokine combination or anti-CD3 stimulation.
Suppression of HIV-1 Replication in Latently Infected, Rest-
ing CD41 T Cells by Glucocorticoids. Glucocorticoids, a class
of hormones with broad antiinflammatory and immuno-
regulatory properties (34–36), have been shown to block
HIV-1 replication in vitro and in vivo (37, 38). One of the
major effects of glucocorticoids is to inhibit the secretion
and effects of cytokines (39–41). In addition, it has been
shown that glucocorticoids can block nuclear factor kB–
mediated cellular activation in vitro (42). To examine the
inhibitory role of glucocorticoids in the induction of HIV-1
replication in latently infected, resting CD41 T cells by cy-
tokines, dexamethasone was added to cultures containing
the combination of three cytokines or anti-CD3 antibody.
As shown in Fig. 4, cultures containing dexamethasone
markedly inhibited replication of HIV-1 in latently in-
fected, resting CD41 T cells from antiretroviral drug–naive
patients when cultures were stimulated with either the
combination of IL-2, IL-6, and TNF-a or with anti-CD3
antibody.
Discussion
In this study, we have examined the synergistic role of
cytokines in the reactivation of HIV-1 replication in la-
tently infected, resting CD41 T cells from patients who
were receiving no antiretroviral therapy as well as from pa-
tients who were receiving HAART and in whom plasma
viremia was markedly suppressed, and in certain patients
even undetectable by the ultrasensitive reverse transcriptase
PCR. Despite the fact that certain proinflammatory and
immunoregulatory cytokines have been shown to upregu-
late the expression of HIV-1 in chronically infected cell
lines and in the PBMCs of infected individuals (3, 10–13),
it has been unclear what effect they have on latently in-
fected, resting CD41 T cells. This study clearly demon-
strates a synergistic role of the combination of IL-2, IL-6,
and TNF-a in the induction of HIV-1 replication in la-
tently infected, resting CD41 T cells. The fact that individ-
ual cytokines did not induce significant replication of HIV
in these cells, whereas combinations of cytokines were po-
tent inducers, is consistent with previous observations of
the synergistic effects of certain cytokines in the induction
of expression of HIV from chronically infected cell lines
Figure 4. Suppression of induction of HIV-1 replication in latently in-
fected, resting CD41 T cells stimulated with the combination of cyto-
kines or anti-CD3 antibody by in vitro glucocorticoids. Resting CD41 T
cells were incubated with IL-2, IL-6, and TNF-a, or with anti-CD3 an-
tibody with irradiated feeders in the presence or absence of dexametha-
sone (1028 M). Supernatants from each culture were removed on days 3,
6, and 9, and HIV-1 p24 was measured by ELISA.89 Chun et al.
(12). HIV-1 replication in latently infected, resting CD41
T cells induced by the three cytokine combination and
anti-CD3 stimulation was effectively suppressed by dexa-
methasone at modest concentrations (1028 M), which agrees
with previous findings that glucocorticoids can block HIV-1
replication by inhibiting the secretion of certain cytokines,
particularly proinflammatory cytokines (39–41) or by inhib-
iting nuclear factor kB–mediated cellular activation (42).
The findings in our study suggest that combinations of
cytokines secreted in response to nonspecific stimuli or as a
result of a specific antigenic stimulus could explain at least
in part the reappearance of plasma viremia in patients re-
ceiving HAART in whom HIV-1 replication was success-
fully contained initially but in whom therapy was subse-
quently interrupted (33). Given the fact that the latently
infected pool of resting CD41 T cells resides predomi-
nantly in lymphoid tissue (27), and since cells situated in
the microenvironment of lymphoid tissue are continually
exposed to the secretion of proinflammatory and immuno-
regulatory cytokines (43), it is highly likely that these cy-
tokines readily induce HIV replication in latently infected,
resting CD41 T cells in the absence of HAART or when
HAART is ineffective in completely suppressing virus rep-
lication (33). The fact that latently infected, resting CD41
T cells from individuals receiving HAART and in whom
plasma viremia was markedly suppressed, and in certain pa-
tients even undetectable, could be readily induced to repli-
cate virus when cells were taken ex vivo and cultured in
the presence of the combination of cytokines is highly con-
sistent with their ability to become reactivated when in
vivo HAART is discontinued. The ability of in vitro
HAART to again suppress cytokine-induced virus replica-
tion underscores this observation.
Finally, given the relatively long half-life of these latently
infected, resting CD41 T cells (24–26) and the fact that
they are constantly within an environment capable of pro-
viding the stimuli for reactivation, it is not unreasonable to
explore strategies aimed at deliberately diminishing the size
of this pool of cells. In this regard, since cytokine-mediated
induction of HIV-1 replication in these cells with subse-
quent release of virus probably results in death of the cell
(44–46), and since the presence of HAART in vitro pre-
vents spread of released virus, it is conceivable that in vivo
administration of cytokines together with HAART may
have such an effect.
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